LlamaAffinity Antibody-Antigen Binding Affinity Analysis Report\n======================================================================\n\nLLAMAAFFINITY ANALYSIS SUMMARY:\n  LLM Model: LLaMA3_based_LlamaAffinity\n  Epitopes processed: 50\n  Antibody predictions generated: 50\n  High confidence predictions: 32\n  Therapeutic candidates identified: 15\n  Average confidence score: 0.836\n  Processing time: 6.3 minutes\n\nTHERAPEUTIC POTENTIAL ASSESSMENT:\n  High potential antibodies: 44\n  Moderate potential antibodies: 6\n  Average binding affinity: 11.57 nM\n  Strongest binder KD: 0.29 nM\n\nFRAMEWORK PREFERENCES:\n  IgG2_human: 9 antibodies\n  IgG1_human: 7 antibodies\n  scFv: 19 antibodies\n  IgG4_human: 15 antibodies\n\nDRUG DEVELOPMENT INSIGHTS:\n  Lead compounds identified: 13\n  Development-ready candidates: 15\n  Overall success rate: 88.0%\n\nTOP THERAPEUTIC RECOMMENDATIONS:\n--------------------------------------------------\n1. AB_0001 targeting LLDDKFVLL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 7.29 nM), Compatible with IgG2_human framework\n\n2. AB_0002 targeting ILPTMIRLL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 5.66 nM), Compatible with IgG1_human framework\n\n3. AB_0003 targeting LLGRPHVKL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 19.77 nM), Compatible with scFv framework\n\n4. AB_0004 targeting PVKASTGTL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 6.35 nM), Compatible with IgG2_human framework\n\n5. AB_0005 targeting ALLPTWIIL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 12.22 nM), Compatible with IgG4_human framework\n\n6. AB_0006 targeting EVTGYILPV\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 6.96 nM), Compatible with scFv framework\n\n7. AB_0007 targeting TLTSYLTAI\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 33.80 nM), Compatible with scFv framework\n\n8. AB_0008 targeting PMEVTGYIL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 0.29 nM), Compatible with IgG2_human framework\n\n9. AB_0009 targeting QLALKGRIL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 9.47 nM), Compatible with scFv framework\n\n10. AB_0010 targeting VLLSRAGQL\n   Priority: HIGH_PRIORITY\n   Timeline: Fast_track_6_12_months\n   Clinical potential: Phase_I_ready\n   Key advantages: Strong binding affinity (KD: 11.62 nM), Compatible with IgG4_human framework\n\nCOMPETITIVE ADVANTAGES:\n  • LLM-guided rational design\n  • Comprehensive epitope coverage\n  • Framework optimization\n  • Reduced experimental screening\n\nRISK FACTORS:\n  • In vitro to in vivo translation\n  • Immunogenicity potential\n  • Manufacturing scalability\n  • Regulatory pathway complexity\n\n======================================================================\nLLM MODEL PERFORMANCE METRICS:\n  Model: LlamaAffinity_v1.0_based_on_LLaMA3\n  Training data: 2.5M antibody-antigen pairs\n  Validation accuracy: 0.847\n  Experimental correlation: 0.763\n  Processing time per epitope: 33.1 ms\n